Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol Myers Squibb has expanded its direct-to-consumer (DTC) sales of medicines in the US with the addition of its psoriasis therapy Sotyktu. All of the DTC channels offer discounts for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback